No Picture
News

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2023 and revenues for 2023. … […]

[adinserter block="3"]
News

Accelerate your science at Chiesi’s Pharma Day

MassBio is partnering with Chiesi on May 29, 2024, to host 2024 Chiesi Pharma Day, an unparalleled opportunity for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. Chiesi Global Rare Diseases was founded in February 2020 and based in Boston, established to deliver innovative therapies and solutions… … […]

[adinserter block="3"]
No Picture
News

Children in detention lack adequate health care, report finds

Children living in detention typically have a host of health problems—including high rates of mental illness, trauma, high-risk substance abuse, chronic disease, and neurodevelopmental disabilities—but lack adequate health services in places where they’re detained, according to a new report. … […]

News

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $BGNE #BeiGene–BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data… … […]

[adinserter block="3"]